Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer

Fig. 2

Colon cancer cell lines with BCL2L1 gain are more sensitive to BCL-XL inhibitor. a Structure of the potent and specific BCL-XL inhibitor A-1155463. b Colorectal cell lines were treated with increasing concentrations of A-1155463. Cells were assayed for viability after 72 h. Results were normalized to cells without treatment. Each cell line was treated with A-1155463 in at least 3 different experiments and the average EC50 is presented. BCL2L1 copy number gain >3 is indicated with + or -. Mutation status of APC and β-catenin is also indicated with + or -. These data are taken from the CCLE database [24]. N denotes cases where data were not available

Back to article page